You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

TETRACYCLINE HYDROCHLORIDE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for tetracycline hydrochloride and what is the scope of patent protection?

Tetracycline hydrochloride is the generic ingredient in fourteen branded drugs marketed by Avet, Bristol, Warner Chilcott, Pharmacia And Upjohn, Solvay, Wyeth Ayerst, Apothecon, Angus, Abbott, Amneal Pharms Ny, Ani Pharms, Aurobindo Pharma Usa, Breckenridge, Chartwell Tetra, Elkins Sinn, Ferrante, Heather, Hikma, Impax Labs, Ivax Sub Teva Pharms, Mast Mm, Purepac Pharm, Pvt Form, Roxane, Strides Pharma, Sun Pharm Industries, Superpharm, Valeant Pharm Intl, Watson Labs, Pfipharmecs, Schiff And Co, Shire, Lederle, Pfizer, Storz, Endo Operations, Alpharma Us Pharms, and Proter, and is included in fifty-three NDAs. Additional information is available in the individual branded drug profile pages.

There are forty-nine drug master file entries for tetracycline hydrochloride. Eight suppliers are listed for this compound.

Summary for TETRACYCLINE HYDROCHLORIDE
US Patents:0
Tradenames:14
Applicants:38
NDAs:53
Drug Master File Entries: 49
Finished Product Suppliers / Packagers: 8
Raw Ingredient (Bulk) Api Vendors: 84
Clinical Trials: 227
What excipients (inactive ingredients) are in TETRACYCLINE HYDROCHLORIDE?TETRACYCLINE HYDROCHLORIDE excipients list
DailyMed Link:TETRACYCLINE HYDROCHLORIDE at DailyMed
Recent Clinical Trials for TETRACYCLINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lao-Oxford-Mahosot Hospital Wellcome Trust Research UnitPhase 2/Phase 3
Mahidol Oxford Tropical Medicine Research UnitPhase 2/Phase 3
Universidade Federal do ParaPhase 3

See all TETRACYCLINE HYDROCHLORIDE clinical trials

Pharmacology for TETRACYCLINE HYDROCHLORIDE

US Patents and Regulatory Information for TETRACYCLINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Proter TETRACYCLINE HYDROCHLORIDE tetracycline hydrochloride SUSPENSION;ORAL 060446-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pharmacia And Upjohn PANMYCIN tetracycline hydrochloride TABLET;ORAL 061705-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pfizer TETRACYN tetracycline hydrochloride INJECTABLE;INJECTION 060096-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Warner Chilcott CYCLOPAR tetracycline hydrochloride CAPSULE;ORAL 062332-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mast Mm TETRACYCLINE HYDROCHLORIDE tetracycline hydrochloride CAPSULE;ORAL 062085-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.